Andrew Witty

Sir Andrew Philip Witty (born 22 August 1964) is a British businessman who served as the chief executive officer of UnitedHealth Group, America's largest healthcare company, from February 2021 to May 2025. Previously, Witty spent 32 years at GlaxoSmithKline, rising to become its CEO from 2008 to 2017. Knighted in 2012 for his contributions to the UK economy and pharmaceutical industry, Witty's tenure at UnitedHealth was marked by record profits but also intense controversy over insurance claim denials and the shocking assassination of UnitedHealthcare CEO Brian Thompson in December 2024.

Early life and education

Andrew Philip Witty was born on 22 August 1964 in Nantwich, a market town in Cheshire, England. He was raised by his parents, Lawrence and Bernadette Witty, alongside his siblings Laurena and Thomas. His father worked in manufacturing, while his mother was a homemaker who instilled strong values of education and hard work in their children.

Witty attended Nantwich and Acton Grammar School (now known as Malbank School), a state grammar school where he excelled academically. He developed an early interest in economics and business, influenced partly by the economic transformations occurring in Britain during the Thatcher era of the 1980s.

He proceeded to the University of Nottingham, where he earned a bachelor's degree in economics. During his time at Nottingham, Witty was active in student affairs and developed the analytical and leadership skills that would define his career. He graduated in the mid-1980s, entering the workforce during a period of significant change in British industry.

Career

GlaxoSmithKline (1985–2017)

In 1985, fresh out of university, Witty joined Glaxo UK (which would later become GlaxoSmithKline following mergers) as a management trainee. This began a 32-year career at one of the world's largest pharmaceutical companies.

Witty's rise through GSK was methodical and impressive. He held various roles across different geographies, gaining experience in sales, marketing, and general management. His international postings included stints in Asia, Africa, and the United States, giving him a global perspective rare among pharmaceutical executives of his generation.

By the early 2000s, Witty had risen to senior leadership roles. In 2003, he was appointed president of GSK's European operations. In 2005, he became president of global manufacturing and supply, overseeing the company's vast production network.

In 2008, at age 43, Witty was named CEO of GlaxoSmithKline, succeeding Jean-Pierre Garnier. He became one of the youngest CEOs of a major pharmaceutical company.

CEO of GSK (2008–2017)

Witty's tenure as GSK CEO was marked by both achievements and controversies:

Access to Medicine – Witty championed initiatives to make medicines more accessible in developing countries, implementing tiered pricing strategies and supporting the development of treatments for neglected tropical diseases. This earned him praise from global health advocates.

China Bribery Scandal – In 2013-2014, GSK was embroiled in a major bribery scandal in China, where the company was found to have used travel agencies to funnel bribes to doctors and health officials to boost drug sales. GSK was fined $489 million by Chinese authorities—the largest corporate fine in Chinese history at the time. Witty publicly apologized and accepted responsibility, though critics argued he should have known about the practices earlier.

Operational Changes – Witty restructured GSK's research and development, shifted compensation models to reduce incentives for aggressive sales practices, and invested in vaccines and consumer healthcare.

Financial Performance – GSK's stock price and earnings per share grew modestly during Witty's tenure, though the company lagged some competitors in bringing blockbuster drugs to market.

Witty stepped down as GSK CEO in 2017, succeeded by Emma Walmsley. He was widely respected in the pharmaceutical industry for his integrity and commitment to global health, despite the China scandal.

Post-GSK Roles (2017–2021)

After leaving GSK, Witty took on several high-profile roles:

• WHO Special Envoy – Appointed by World Health Organization Director-General Tedros Adhanom Ghebreyesus
• COVID-19 Therapeutics Accelerator – Co-chair, working to speed development of COVID treatments
• University of Nottingham – Served as Chancellor from 2013–2017

In July 2018, Witty joined UnitedHealth Group as CEO of Optum, the company's health services division. This marked his entry into the American healthcare system—a dramatic shift from pharmaceuticals to health insurance and services.

UnitedHealth Group (2021–2025)

In February 2021, Witty was promoted to CEO of UnitedHealth Group, succeeding David Wichmann. UnitedHealth is the largest healthcare company in the United States and ranks in the top 10 of the Fortune 500, with annual revenues exceeding $370 billion.

Under Witty's leadership, UnitedHealth continued its aggressive growth:

• Revenues increased from $287 billion (2021) to over $370 billion (2024)
• Market capitalization exceeded $500 billion
• Profit margins remained robust despite industry challenges
• The company expanded its Optum division, which provides healthcare services, pharmacy benefits, and data analytics

However, Witty's tenure was increasingly controversial:

Claim Denial Controversies

UnitedHealthcare (the insurance arm of UnitedHealth Group) faced intense criticism for denying medical claims at high rates. Data showed that UnitedHealthcare's initial denial rate for post-acute care prior authorization requests jumped from 8.7% in 2019 to 22.7% by 2022.

Critics, including physicians and patient advocates, accused the company of using algorithms and aggressive utilization review to deny legitimate claims in order to maximize profits. Congressional investigations examined UnitedHealth's practices.

DOJ Antitrust Investigation

In 2024, the Department of Justice launched an antitrust investigation into UnitedHealth's acquisitions and market power. A class-action lawsuit filed in May 2024 alleged that Witty and other executives sold $120 million in company stock after learning of the investigation but before informing investors—potentially constituting insider trading.

Brian Thompson Assassination (December 2024)

On December 4, 2024, Brian Thompson, the CEO of UnitedHealthcare (UnitedHealth Group's insurance division), was shot and killed outside the New York Hilton Midtown in Manhattan. Thompson was arriving for an investor conference when he was ambushed by a masked gunman. Police found bullet casings inscribed with the words "deny," "defend," and "depose"—a reference to insurance industry tactics for avoiding claim payouts.

The assassination shocked corporate America and focused intense scrutiny on the health insurance industry. Many social media users expressed little sympathy for Thompson, with some celebrating his death—a disturbing indication of deep public anger toward health insurers.

Witty responded with a private video message to employees that was later leaked. In it, he defended the company's practices and criticized "vitriolic" attacks on the industry as "not in tune with reality." His response was widely condemned as tone-deaf and disconnected from the frustration millions of Americans feel when dealing with insurance denials.

The suspected killer, Luigi Mangione, was arrested on December 9, 2024. Investigations revealed Mangione had allegedly suffered from chronic back pain and blamed the healthcare system for inadequate treatment.

Resignation (May 2025)

On May 15, 2025, UnitedHealth Group announced that Andrew Witty would step down as CEO, effective immediately. The company stated Witty was "pursuing other opportunities," but industry observers believed the decision was related to the Thompson assassination, the subsequent public relations crisis, ongoing federal investigations, and mounting pressure from investors concerned about reputational damage.

Witty was succeeded by Stephen Hemsley, who returned from retirement to stabilize the company. Witty's departure marked an ignominious end to a career that had included a knighthood and leadership of two of the world's most important healthcare companies.

Personal life

Andrew Witty is married to Caroline Hall. The couple met in the late 1980s while both were working in London. They married in the early 1990s and have two children together. The family has lived in Buckinghamshire, England for many years, though Witty maintained residences in the United States during his time at United Health.

Witty is known as a marathon runner and completed the London Marathon in 2008, shortly after becoming GSK CEO. He has spoken about using running as a way to manage stress and maintain health during demanding periods of his career.

Despite his wealth and senior corporate positions, colleagues describe Witty as relatively approachable and lacking the arrogance sometimes associated with pharmaceutical and insurance executives. However, his response to the Thompson assassination damaged this reputation significantly.

Controversies

GSK China Bribery Scandal (2013-2014)

The largest controversy of Witty's GSK tenure was the revelation that GSK China had systematically bribed doctors, hospital administrators, and government officials to boost drug sales. The scheme involved using travel agencies to funnel money as bribes disguised as conference expenses and travel costs.

Chinese authorities investigated for months before announcing in 2014 that GSK would be fined 3 billion yuan ($489 million)—the largest corporate fine in Chinese history. Several GSK China executives were given prison sentences.

Witty flew to China to personally apologize and promised reforms. He stated: "We have made fundamental changes to our business model in China, changes which we are now rolling out globally. We are determined this will not happen again."

Critics argued Witty should have been aware of the practices given their scale and duration. However, no evidence emerged that Witty personally knew of or authorized the bribery. His willingness to take responsibility and implement global reforms was seen as appropriate crisis management.

Health Insurance Claim Denials

At UnitedHealth, Witty faced relentless criticism over the company's high rates of claim denials. Physicians reported that UnitedHealthcare was denying necessary treatments, often using algorithmic review systems that seemed designed to maximize denials.

A 2023 investigation found that UnitedHealthcare was using an AI algorithm with a 90% error rate to deny claims for post-acute care. When providers appealed, the vast majority of denials were overturned—suggesting the initial denials were unjustified.

Witty defended UnitedHealth's practices, arguing that utilization review was necessary to prevent unnecessary care and control costs. However, the company's 22.7% denial rate for post-acute care far exceeded industry norms and seemed to contradict Witty's claims about promoting appropriate care.

Response to Brian Thompson Assassination

Witty's response to Thompson's murder was widely criticized. In a leaked video to employees, he characterized criticism of the health insurance industry as "vitriolic" and "aggressive," and defended UnitedHealth's business practices.

His failure to acknowledge the legitimate grievances of patients who had been denied coverage, or to express understanding of why so many Americans were angry at health insurers, struck many as tone-deaf. Some argued he should have used the moment to announce reforms to claims processes rather than defending the status quo.

The incident highlighted a profound disconnect between health insurance executives—who viewed their companies as efficiently managing healthcare costs—and ordinary Americans who experienced the system as bureaucratic, profit-driven, and designed to deny care.

Alleged Insider Trading

The May 2024 class-action lawsuit alleged that Witty, Thompson, and former CEO Stephen Hemsley sold $120 million in UnitedHealth stock between November 2023 and February 2024 after learning of a DOJ antitrust investigation but before informing investors. Thompson alone allegedly netted $15 million from these sales.

If proven, these sales would constitute illegal insider trading. Witty's attorneys denied wrongdoing, arguing the stock sales were part of pre-planned trading programs. As of mid-2025, the lawsuit remained pending.

Awards and recognition

• Knight Bachelor (2012) – Knighted by Queen Elizabeth II for services to the economy and UK pharmaceutical industry
• Honorary Citizen of Singapore (2018) – Awarded for contributions to healthcare and medicine
• Chancellor of the University of Nottingham (2013-2017) – His alma mater honored him with its highest ceremonial position

Compensation and net worth

Witty's 2024 compensation from UnitedHealth Group totaled $26.3 million, making him the highest-paid CEO among major health insurers. The breakdown included:

• Base salary: $1.4 million
• Stock awards: $18.5 million
• Option awards: $4.2 million
• Other compensation: $2.2 million

His net worth is estimated at over $100 million, accumulated through stock holdings and compensation from GSK and UnitedHealth over his decades-long career.